ArticleFrontiers in pharmacology2026
Sacituzumab tirumotecan in an advanced HR+/HER2-breast cancer patient with bone marrow metastasis-induced refractory thrombocytopenia: a case report and literature review.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone marrow metastasis (BMM) is an adverse prognostic factor in advanced breast cancer and may cause severe myelosuppression, particularly refractory thrombocytopenia, thereby limiting systemic therapy. Sacituzumab tirumotecan (sac-TMT) is a Trop-2-directed antibody-drug conjugate (ADC), but evidence for its use in patients with severe thrombocytopenia and compromised bone marrow reserve remains limited. We report a real-world case of sac-TMT use in this challenging clinical setting and discuss relevant considerations regarding ADC resistance and treatment sequencing. Case Presentation: A 62-year-old postmenopausal woman (BMI: 16.23 kg/m Conclusion: Sac-TMT combined with intensive hematologic supportive care was feasible in this heavily pretreated HR+/HER2 - breast cancer patient with BMM-induced refractory thrombocytopenia. Platelet stabilization, reduced transfusion dependence, and clinical disease stability were observed before PET-CT-confirmed progression. Further case series and prospective studies are needed to validate the feasibility and safety of this approach in similar high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.